Skip to content
Screener

Integra LifeSciences IART Wound Reconstruction Solutions — Total Revenues

Similar metrics at other companies

Xerox Holdings Corporation logo
XRXIT Solutions — Total Revenues
$194M-8.9%
AMR
AMRZAggregates and other construction materials — Total Revenues
$764M+11.0%
ESP
ESPRCollaboration revenue — Total Revenues
$36.71M+22.0%
CME Group logo
CMEOther Revenue — Total Revenues
$115.6M+9.2%
AMR
AMRZInterproduct revenues — Total Revenues
-$101M-1.0%
NorthWestern Energy Group, Inc. logo
NWETotal Revenue — Total Revenues
$497.57M+6.6%

Other financials

Income statement

See full
Revenue$418.8M+0.8%
Gross profit$219.7M+5.0%
Operating income$19.3M+104%
Net income$4.5M+101%
EPS (diluted)$0.06+101%

Balance sheet

See full
Cash & equivalents$214.4M-1.6%
Total debt$2.0B+3.2%
Total equity$1.0B+0.5%
Total assets$3.6B-2.8%

Cash flow

See full
Operating cash flow$22.8M+156%
CapEx$12.3M-38.9%
Free cash flow$10.5M+193%

Valuation

See full
Market cap$1.38B+42.7%
Enterprise value$3.13B+17.9%
P/S0.8×+0.2×

Profitability

See full
Gross margin52.5%-0.1pp
Operating margin2.6%+1.3pp
Net margin-0.4%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-0.7%
Debt / equity1.9×+0.1×
Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000917520-26-000058
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Neurosurgery$213,264$208,992$411,458$399,904
Surgical Instruments54,80653,080102,039104,030
ENT Solutions41,19941,88678,90780,688
Total Specialty Surgery309,269303,958592,404584,622
Wound Reconstruction Solutions81,30584,747160,952159,526
Private Label28,18726,90057,32354,110
Total Tissue Reconstruction109,492111,647218,275213,636
Total Revenue$418,761$415,605$810,679$798,258

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's wound reconstruction solutions — total revenues?
Integra LifeSciences (IART) reported wound reconstruction solutions — total revenues of $81.31M in Q2 2026.
What does wound reconstruction solutions — total revenues mean?
This metric represents the total revenue generated from the sale of products and services within the wound reconstruction solutions portfolio. It reflects the company's market performance in regenerative medicine and tissue repair applications, serving as a key indicator of demand for advanced surgical wound care technologies. Investors use this figure to assess the growth trajectory and competitive positioning of the firm's specialized regenerative therapy business segment.

Ask your AI about Integra LifeSciences's wound reconstruction solutions — total revenues.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude